Results 81 to 90 of about 505,925 (298)

Targeted DNA vaccines for enhanced induction of Idiotype (Id)-specific B and T cells

Frontiers in Oncology, 2012
Background: Idiotopes (Id) are antigenic determinants localized in variable (V) regions of Ig. Id-specific T and B cells (antibodies) play a role in immunotherapy of Id+ tumors.
Agnete Brunsvik Fredriksen, Inger eSandlie, Bjarne eBogen   +2 more
doaj   +1 more source

Antigen Presenting Cells [PDF]

, 2005
Preface. List of Contributors. List of Abbreviations. Color Plates. Part I: Antigen Presentation in the Immune System. 1 Some Old and Some New Findings on Antigen Processing and Presentation (Emil R. Unanue). 1.1 Introduction. 1.2 HEL Processing. 1.3 Selection of Peptide Segments of HEL. 1.4 HEL: Conformational Isomers.
openaire   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Mesenchymal stromal cells 2.0: thinking outside the box

Frontiers in Immunology
Mesenchymal stromal cells (MSCs) are non-hematopoietic progenitor cells that can be derived from a variety of sources including bone marrow and adipose tissues among others.
Gabrielle A. Mandl, Malak Lahrichi, Perla Matar, Jamilah Abusarah, Roudy Farah, Jean Pierre Bikorimana, Abba Cisse, Moutih Rafei, Moutih Rafei, Moutih Rafei   +9 more
doaj   +1 more source

Influenza and memory T cells : how to awake the force [PDF]

, 2016
Annual influenza vaccination is an effective way to prevent human influenza. Current vaccines are mainly focused on eliciting a strain-matched humoral immune response, requiring yearly updates, and do not provide protection for all vaccinated individuals.
Glezen, Hartshorn, Hufford, Jin, Jordan, Luo, Mosmann, Razvi, Topham, Topham, Topham, Von Andrian, Wijburg   +12 more
core   +3 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery [PDF]

, 2013
Protein-based vaccine development faces the difficult challenge of finding robust yet non-toxic adjuvants suitable for humans. Here, using a molecular engineering approach, we have developed a molecular platform for generating self-adjuvanting immunogens
A Demissie, A Raja, A Regnault, A Williams, AF Cunningham, AN Antoniou, AR Berengian, AS Mustafa, B Heyman, BC Schalke, CK Kennaway, Craig van Dolleweerd, CT Cady, D Chargelegue, D Matheoud, DH Schuurhuis, E Celis, E Celis, EJ Wiersma, Elena Stylianou, EM Leyten, F Manca, F Pinheiro da Silva, F Villinger, F Winau, G Falero-Diaz, G Terres, GG Klaus, Gil Reynolds Diogo, H Boesen, Ilaria Pepponi, J Laissue, JM den Haan, Julian K.-C. Ma, K Osato, KB Reid, M Jacobsen, Matthew J. Paul, MF Bachmann, N Caccamo, N Polyanskaya, P Andersen, Pascal M. W. Drake, PD Simitsek, Pere-Joan Cardona, PM Guyre, PM Hogarth, PS Jackett, Q Li, R Jemmerson, R Pal, R Reljic, R Reljic, Rajko Reljic, RG Taylor, RJ Eisenberg, RJ Wilkinson, S Marusic-Galesic, SA Moreno-Mendieta, SA Plotkin, U Abdel-Motal, V Roupie, W Phoolcharoen, WE Houston, WR Heath, Y Yuan, Y Yuan, YM Wen, Z Chang   +68 more
core   +2 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source